| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
-- Strong U.S. launch momentum for IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
-- U.S. launch of IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- |
| 25 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 24, 2026, Rhythm Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the close of business on the April 27, 2026 record date (the “Record Date”) for the Annual Meeting, there w... |
| 15 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
-- IMCIVREE® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- |
| 03 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
-- Kim Popovits appointed as new Director; Ed Mathers to depart -- |
| 26 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment |
| 20 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity |
| 16 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
-- Four substudies did not meet pre-specified primary endpoints -- |
| 02 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- |
| 09 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
© Rhythm® Pharmaceuticals, Inc. All rights reserved. ® Rhythm Pharmaceuticals Corporate Presentation January 2026 EXHIBIT 99.2 |
| 19 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 16, 2025, Camille L. Bedrosian, M.D. notified the Board of Directors (the “Board”) of Rhythm Pharmaceuticals, Inc. (the “Company”) of her decision to resign from the Board, effective immediately. Dr. Bedrosian currently serve... |
| 11 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome |
| 07 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE®(setmelanotide) for Patients with Acquired Hypothalamic Obesity |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
-- Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million -- |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
-- Second quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $48.5 million -- |
| 11 Jul 2025 |
8-K: Other Events
Rhythm Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representati... |
| 09 Jul 2025 |
8-K: Regulation FD Disclosure; Other Events
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity |
| 26 Jun 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Rhythm Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: |
Loading...